Ali Alhoshani1, Fahad O Alatawi1, Fawaz E Al-Anazi1, Ibraheem M Attafi2, Asad Zeidan3, Abdelali Agouni4, Heba M El Gamal4, Licia S Shamoon4, Sarah Khalaf4, Hesham M Korashy4. 1. Department of Pharmacology & Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. 2. Poison Control & Medical Forensic Chemistry Center, Jazan Health Affairs, Jazan, Saudi Arabia. 3. Department of Biomedical Sciences, College of Medicine, QU Health, Qatar University, Doha, Qatar. 4. Department of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, Doha, Qatar.
Abstract
INTRODUCTION: Venetoclax (VCX) is a selective BCL-2 inhibitor approved for the treatment of leukemia and lymphoma. However, the mechanisms of anti-cancer effect of VCX either as a monotherapy or in combination with other chemotherapeutic agents against breast cancer need investigation. METHODS: Breast cancer cell lines with different molecular subtypes (MDA-MB-231, MCF-7, and SKBR-3) were treated with different concentrations of VCX for indicated time points. The expression of cell proliferative, apoptotic, and autophagy genes was determined by qRT-PCR and Western blot analyses. In addition, the percentage of MDA-MB-231 cells underwent apoptosis, expressed higher oxidative stress levels, and the changes in the cell cycle phases were determined by flow cytometry. RESULTS: Treatment of human breast cancer cells with increasing concentrations of VCX caused a significant decrease in cells growth and proliferation. This effect was associated with a significant increase in the percentage of apoptotic MDA-MB-231 cells and in the expression of the apoptotic genes, caspase 3, caspase 7, and BAX, with inhibition of anti-apoptotic gene, BCL-2 levels. Induction of apoptosis by VCX treatment induced cell cycle arrest at G0/G1 phase with inhibition of cell proliferator genes, cyclin D1 and E2F1. Furthermore, VCX treatment increased the formation of reactive oxygen species and the expression level of autophagy markers, Beclin 1 and LC3-II. Importantly, these cellular changes by VCX increased the chemo-sensitivity of MDA-MB-231 cells to doxorubicin. DISCUSSION: The present study explores the molecular mechanisms of VCX-mediated inhibitory effects on the growth and proliferation of TNBC MDA-MB-231 cells through the induction of apoptosis, cell cycle arrest, and autophagy. The study also explores the role of BCL-2 as a novel targeted therapy for breast cancer.
INTRODUCTION: Venetoclax (VCX) is a selective BCL-2 inhibitor approved for the treatment of leukemia and lymphoma. However, the mechanisms of anti-cancer effect of VCX either as a monotherapy or in combination with other chemotherapeutic agents against breast cancer need investigation. METHODS: Breast cancer cell lines with different molecular subtypes (MDA-MB-231, MCF-7, and SKBR-3) were treated with different concentrations of VCX for indicated time points. The expression of cell proliferative, apoptotic, and autophagy genes was determined by qRT-PCR and Western blot analyses. In addition, the percentage of MDA-MB-231 cells underwent apoptosis, expressed higher oxidative stress levels, and the changes in the cell cycle phases were determined by flow cytometry. RESULTS: Treatment of human breast cancer cells with increasing concentrations of VCX caused a significant decrease in cells growth and proliferation. This effect was associated with a significant increase in the percentage of apoptotic MDA-MB-231 cells and in the expression of the apoptotic genes, caspase 3, caspase 7, and BAX, with inhibition of anti-apoptotic gene, BCL-2 levels. Induction of apoptosis by VCX treatment induced cell cycle arrest at G0/G1 phase with inhibition of cell proliferator genes, cyclin D1 and E2F1. Furthermore, VCX treatment increased the formation of reactive oxygen species and the expression level of autophagy markers, Beclin 1 and LC3-II. Importantly, these cellular changes by VCX increased the chemo-sensitivity of MDA-MB-231 cells to doxorubicin. DISCUSSION: The present study explores the molecular mechanisms of VCX-mediated inhibitory effects on the growth and proliferation of TNBC MDA-MB-231 cells through the induction of apoptosis, cell cycle arrest, and autophagy. The study also explores the role of BCL-2 as a novel targeted therapy for breast cancer.
Authors: Charles A Easley; Joshua M Bradner; Amber Moser; Chelsea A Rickman; Zachary T McEachin; Megan M Merritt; Jason M Hansen; W Michael Caudle Journal: Stem Cell Res Date: 2015-03-25 Impact factor: 2.020
Authors: Reema Wahdan-Alaswad; Zeying Fan; Susan M Edgerton; Bolin Liu; Xin-Sheng Deng; Sigrid Salling Arnadottir; Jennifer K Richer; Steven M Anderson; Ann D Thor Journal: Cell Cycle Date: 2013-10-03 Impact factor: 4.534
Authors: Homood M As Sobeai; Munirah Alohaydib; Ali R Alhoshani; Khalid Alhazzani; Mashal M Almutairi; Tareq Saleh; David A Gewirtz; Moureq R Alotiabi Journal: Saudi Pharm J Date: 2021-12-31 Impact factor: 4.330
Authors: Dalyia N Benjamin; Tracey R O'Donovan; Kristian B Laursen; Nina Orfali; Mary R Cahill; Nigel P Mongan; Lorraine J Gudas; Sharon L McKenna Journal: Front Oncol Date: 2022-02-24 Impact factor: 6.244
Authors: Andrei V Khokhlatchev; Arati Sharma; Tye G Deering; Jeremy J P Shaw; Pedro Costa-Pinheiro; Upendarrao Golla; Charyguly Annageldiyev; Myles C Cabot; Mark R Conaway; Su-Fern Tan; Johnson Ung; David J Feith; Thomas P Loughran; David F Claxton; Todd E Fox; Mark Kester Journal: FASEB J Date: 2022-10 Impact factor: 5.834